This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10). The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants. At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls. At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls. Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.
BuiALHorwichTBFonarowGC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
2.
BozkurtBMannDLDeswalA. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2009;15(4):331–341.
3.
YndestadADamåsJKØieEUelandTGullestadLAukrustP. Role of inflammation in the progression of heart failure. Curr Cardiol Rep. 2007;9(3):236–241.
4.
DixonDLGriggsKMBerstenADDe PasqualeCG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56(3):593–599.
5.
LevineBKalmanJMayerLFillitHMPackerM. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–241.
6.
LiuLZhaoSP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999;69(1):77–82.
7.
DemopoulosCAPinckardRNHanahanDJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254(19):9355–9358.
8.
MontrucchioGAlloattiGCamussiG. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–1699.
9.
DemopoulosCKarantonisHAntonopoulouS. Platelet activating factor—a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705–716.
10.
ZhaoDChuWFWuL. PAF exerts a direct apoptotic effect on the rat H9c2 cardiomyocytes in Ca2+-dependent manner. Int J Cardiol. 2010;143(1):86–93.
11.
DetopoulouPNomikosTFragopoulouE. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009;42(1-2):44–49.
12.
ShindouHHishikawaDNakanishiH. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA: lyso-PAF acetyltransferase. J Biol Chem. 2007;282(9):6532–6539.
13.
HarayamaTShindouHOgasawaraRSuwabeAShimizuT. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem. 2008;283(17):11097–11106.
14.
SnyderF. CDP-choline: alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997;1348(1-2):111–116.
van VarkLCKardysIBleuminkGS. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study. Eur Heart J. 2006;27(19):2346–2352.
17.
GerberYDunlaySMJaffeAS. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis. 2009;203(2):593–598.
18.
SwedbergKClelandJDargieH. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115–1140.
19.
ChrysohoouCPitsavosCBarbetseasJ. Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the hellenic heart failure study. Congest Heart Fail. 2008;14(5):229–233.
20.
RectorTSCohnJN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124(4):1017–1025.
21.
DemopoulosCAAndrikopoulosNKAntonopoulouS. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids. 1994;29(4):305–309.
22.
BlighEGDyerWJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911–917.
23.
NomikosTNIatrouCDemopoulosCA. Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue. Eur J Biochem. 2003;270(14):2992–3000.
24.
TsouprasABFragopoulouENomikosTIatrouCAntonopoulouSDemopoulosCA. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007;2007:27683.
25.
ChrysohoouCPitsavosCBarbetseasJ. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels. 2009;24(1):22–26.
26.
BozkurtBMannDLDeswalA. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010;15(4):331–341.
27.
SantilliFDaviGBasiliS. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost. 2010;8(5):914–922.
28.
CamussiGBussolinoFSalvidioGBaglioniC. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987;166(5):1390–1404.
29.
BifflWLMooreEEMooreFABarnettCCJrSillimanCCPetersonVM. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J Leukoc Biol. 1996;59(4):569–574.
30.
BraquetPHosfordDKoltzPGuilbaudJPaubert-BraquetM.Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids. 1991;26(12):1071–1075.
31.
BonavidaBMencia-HuertaJMBraquetP.Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion. J Lipid Mediat. 1990;(suppl 2):S65–S76.
32.
RothMNauckMYousefiS. Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor. J Exp Med. 1996;184(1):191–201.
33.
CamussiGMarianoFBianconeL. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol. 1995;155(1):316–324.
34.
DetopoulouPNomikosTFragopoulouE. PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics. Prostaglandins Other Lipid Mediat. 2012;97(1-2):43–49.
35.
ZhangGQTaoYKLiXL. Investigation of platelet activating factor (PAF) in acute myocardial infarction. Chin J Emerg Med. 2010;19(12):1304–1307.
36.
SzmitSJankMMaciejewskiH. Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. J Appl Genet.s 2010;51(3):353–368.
37.
MatsumoriA. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol. 2004;4(2):171–176.
38.
PrandotaJ. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Therap. 2002;9(4):317–328.
39.
GodfreyVFarquharsonCMacdonaldJEYeeCMStruthersAD. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007;117(2):282–284.
40.
TsantilaNTsouprasABFragopoulouEAntonopoulouSIatrouCDemopoulosCA.In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011;62(3):209–218.
41.
HellerRBussolinoFGhigoD. Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Pharmacol. 1992;44(2):223–229.
42.
TolinsJPMelemedASulcinerDGustafsonKSVercellottiGM. Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids. 1991;26(12):1218–1222.
43.
CrawfordSEHuangLHsuehW. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. J Heart Lung Transplant. 1999;18(5):470–477.
44.
SchrorKFelschA. Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. Agents Actions Suppl. 1992;38 (pt 3):209–216.
45.
WhiteHLFaisonLD. Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988;35(6):939–944.
46.
PennaCBassinoEAlloattiG. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood). 2011;236(4):390–401.
47.
KoenigWKhuseyinovaN. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23(1):85–92.
